Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 5 January 2026 - 9 January 2026

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

New York, Jan 8, 2026, 18:23 EST — After-hours Shares of Eli Lilly fell 2.1% on Thursday, trading between $1,070.16 and $1,133.06, and were last at $1,085.19 in after-hours activity after the drugmaker reported late-stage data on a Zepbound-Taltz combination in psoriatic arthritis. Lilly said 31.7% of patients on the combo met a dual goal — at least 50% lower disease activity and at least 10% weight loss after 36 weeks — compared with 0.8% on Taltz alone. Senior vice president Mark Genovese said the results support an “integrated treatment approach” for the inflammatory joint disease, which affects up to
9 January 2026
···
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

New York, Jan 8, 2026, 08:36 EST — Premarket Eli Lilly shares were up 4.1% at $1,108.09 in premarket trade on Thursday after the drugmaker agreed to buy autoimmune-focused biotech Ventyx Biosciences for $1.2 billion in cash. The deal adds oral drugs for inflammatory diseases and a mid-stage program tied to a cardiovascular condition linked to obesity. “We like that Lilly is taking chances on potentially transformative opportunities,” Cantor Fitzgerald analyst Carter Gould said. Reuters The move matters because Lilly’s stock has become a proxy for the weight-loss boom, and investors are now looking for what comes after the first
8 January 2026
····
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

New York, Jan 7, 2026, 17:32 EST — After-hours Shares of Ventyx Biosciences (VTYX.O) jumped on Wednesday after Eli Lilly (LLY.N) agreed to buy the San Diego-based biotech in a $14-per-share all-cash deal. Ventyx closed up about 37% at $13.81 and was last at $13.73 in after-hours trading, still shy of the offer price. Yahoo Finance For Lilly, the deal is a small bolt-on at a moment when the drugmaker is flush from sales of its diabetes and weight-loss medicines. Cantor Fitzgerald analyst Carter Gould called the price tag “borderline immaterial” for Lilly and said the company is taking shots
7 January 2026
·····
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

New York, Jan 7, 2026, 4:55 PM EST — After-hours Eli Lilly and Co shares climbed on Wednesday after the drugmaker agreed to buy Ventyx Biosciences in a $1.2 billion deal, pressing ahead with its push beyond blockbuster diabetes and weight-loss drugs. Lilly stock ended up 4.1% at $1,108.09, after touching $1,117.37, for a market value around $1 trillion. reuters.com The move matters because Lilly’s valuation leaves little room for stumbles. Investors have started to look past the first wave of obesity demand and toward what fills the pipeline later in the decade, especially if pricing gets tougher. Pills are
7 January 2026
····
Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

New York, January 7, 2026, 11:41 EST — Regular session. Eli Lilly and Company shares were up 3.3% at $1,099.44 in late morning trade, pushing back toward the $1,100 level as investors cheered fresh deal chatter around the drugmaker’s pipeline. (https://www.reuters.com/markets/companies/LLY.N/) The lift matters now because the market is watching how Lilly defends its growth run while competitors push pill versions of obesity drugs and pricing stays in flux. Investors have rewarded companies that can keep adding late-stage shots on goal without derailing margins. The Wall Street Journal reported Lilly is in advanced talks to buy Ventyx Biosciences for more
7 January 2026
····
Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

New York, Jan 7, 2026, 05:03 EST — Premarket Ventyx Biosciences shares jumped about 66% before the bell on Wednesday after a report that Eli Lilly is in advanced talks to buy the biotech company for more than $1 billion. The stock traded at $16.70 in premarket action, versus a $10.05 regular-session close. Public The move matters because a confirmed deal would lock in a takeover premium for a company whose value has swung sharply on trial timelines and pipeline expectations. It also tests whether big drugmakers are willing to pay up for clinical-stage assets tied to inflammation and obesity-linked
7 January 2026
······
Eli Lilly stock rises after hours on Nimbus obesity pill deal as Ventyx talks surface

Eli Lilly stock rises after hours on Nimbus obesity pill deal as Ventyx talks surface

New York, January 6, 2026, 18:18 EST — After-hours Eli Lilly and Company stock closed up 2.2% on Tuesday and was up about 0.1% in after-hours trading after Nimbus Therapeutics said it struck a research and licensing deal with the drugmaker to pursue an oral obesity treatment. Yahoo Finance The news lands as investors look for the next leg of growth in obesity care, where convenience matters and pill options could widen uptake beyond weekly injections. Industry forecasts have pegged the obesity-drug market at more than $150 billion a year by the early 2030s, and drugmakers are racing to develop
7 January 2026
····
Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

New York, Jan 6, 2026, 11:34 AM EST — Regular session Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors.com The update lands amid a scramble for new obesity treatments that can add to GLP-1 drugs — a fast-growing market where investors now weigh not just pounds lost, but what kind of weight comes off. Many patients and doctors want therapies that
6 January 2026
···
Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

New York, January 6, 2026, 10:55 EST — Regular session Eli Lilly and Company (LLY) shares rose about 1.6% on Tuesday after Nimbus Therapeutics announced a research and licensing agreement with the drugmaker aimed at developing an oral obesity treatment. Lilly was trading at $1,057.80 in New York morning trade, after moving between $1,040.15 and $1,070.77 earlier in the session. Reuters The tie-up matters because pills could widen access and intensify competition in weight-loss medicines, a market where convenience and price are becoming as important as results. Investors have watched the sector shift from supply constraints toward a more consumer-style
6 January 2026
····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

New York, January 5, 2026, 5:47 PM ET — After-hours Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States. The Washington Post The drop matters because investors have priced Lilly as a long-duration obesity winner, with expectations anchored to rapid growth in demand and tight supply. Any new sign that the market is shifting toward cheaper oral options can force a reset in assumptions about pricing power. GLP-1 drugs,
6 January 2026
·····
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics (VKTX) slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%. The move highlights how sensitive obesity-drug developers remain to pricing signals from the market leaders. Viking has no approved products, so changes in expected pricing can hit the stock as hard as trial data. Direct-to-consumer discounts are also changing how investors think about margins
5 January 2026
······
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

NEW YORK, Jan 5, 2026, 13:54 EST — Regular session Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session. The move came as Novo Nordisk began U.S. sales of a once-daily pill version of Wegovy, bringing a branded oral option into pharmacies at $149 a month for starter doses for self-paying patients, Reuters reported. Novo’s website shows higher-dose pricing at $299 a month, with the 4 mg dose set to
5 January 2026
······
1 … 5 6 7 8 9 … 13

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Go toTop